Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
Siemens Healthineers is joining forces with Novo to help boost awareness and diagnosis of fatty liver disease.
Stories from Fiercebiotech
Use this page to scan recent stories from Fiercebiotech, see the themes that keep appearing, and jump into complete story briefs.
Recent curated reads
Enveda reaps $311M series E to feed ambition to become a ‘household name’
Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.
Novartis secures new radioligand in $900M deal as competition strengthens
As an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a preclinical radioligand therapy from a specialist Chinese biotech.
Vertex’s midstage data amplify kidney disease market opportunity
Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial.
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”
Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures
The Department of War has awarded Flagship Pioneering $47 million to develop medical countermeasure technologies against emerging threats.
Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
Roche has reported a phase 3 win for sefaxersen in kidney disease, teeing up talks with regulators about the path to approval for the Ionis-partnered, would-be blockbuster candidate.
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
GSK has been operating a strategy of “balancing the West and the East” since the Big Pharma’s eyes were opened to the potential of licensing drugs from China two years ago, according to an executive.
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich ataxia (FA) portfolio while locking in three strategic collaborations to support its lead asset.
Cordis’ sirolimus drug-coated balloon earns FDA approval as a breakthrough device
The FDA gave the green light to a first and only sirolimus drug-eluting balloon designed by Cordis to treat coronary in-stent restenosis.
Read this source in the app
Open the app view when you want faster scanning, saved stories, and source-focused reading in one place.